Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Menopause

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/GME.0000000000000196PMID 24473530PMCID PMC4574289
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New generation nonhormonal management for hot flashes

  2013cited by this paper
• Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation

  2013cited by this paper
• Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

  2013cited by this paper
• Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.

  2012cited by this paper
• Joint effects of smoking and gene variants involved in sex steroid metabolism on hot flashes in late reproductive-age women.

  2012cited by this paper
• Contribution of the rate of change of antimüllerian hormone in estimating time to menopause for late reproductive-age women.

  2012cited by this paper
• Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging

  2012cited by this paper
• A GLOBAL MEASURE OF PERCEIVED STRESS

  2012cited by this paper
• Duration of Menopausal Hot Flushes and Associated Risk Factors

  2011cited by this paper
• A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women

  2011cited by this paper
• Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period.

  2011cited by this paper
• Somatic and affective anxiety symptoms and menopausal hot flashes

  2010cited by this paper
• Associations of depression with the transition to menopause

  2010cited by this paper
• Obesity and reproductive hormone levels in the transition to menopause

  2010cited by this paper
• Role of ethnicity in the expression of features of hot flashes.

  2009cited by this paper
• Factors that influence entry into stages of the menopausal transition

  2009cited by this paper
• Duration of vasomotor symptoms in middle-aged women: a longitudinal study

  2009cited by this paper
• Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States

  2008cited by this paper
• Hot flashes and panic attacks: a comparison of symptomatology, neurobiology, treatment, and a role for cognition.

  2008cited by this paper
• Beyond frequency: who is most bothered by vasomotor symptoms?

  2008cited by this paper
• Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis

  2008cited by this paper
• Smoking prevalence among women of reproductive age--United States, 2006.

  2008cited by this paper
• Ethnicity and Vasomotor Symptoms in Postmenopausal Women

  2007cited by this paper
• Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation.

  2006cited by this paper
• Association between race and hot flashes in midlife women.

  2006cited by this paper
• The role of anxiety and hormonal changes in menopausal hot flashes

  2005cited by this paper
• National Institutes of Health State-of-the-Science Conference Statement: Management of Menopause-Related Symptoms

  2005cited by this paper
• Anxiety, hormonal changes, and vasomotor symptoms during the menopause transition.

  2005cited by this paper
• Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age.

  2004cited by this paper
• Psychometric properties of a menopausal symptom list

  2003cited by this paper
• Hot Flashes in the Late Reproductive Years: Risk Factors for African American and Caucasian Women

  2001cited by this paper
• Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women.

  1999cited by this paper
• A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

  1996cited by this paper
• Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking.

  1986cited by this paper
• Longitudinal data analysis using generalized linear models

  1986cited by this paper
• A global measure of perceived stress.

  1983cited by this paper
• The CES-D Scale

  1977cited by this paper
• A rating instrument for anxiety disorders.

  1971cited by this paper

• A cross-sectional cohort study of menopause-related symptoms in British Columbia.

  2026cites this paper
• Quality of life and associated factors in climacteric women surviving gynecological cancer: an observational study.

  2026cites this paper
• Síntomas vasomotores y alteraciones del sueño y anímicas en el climaterio: nuevas perspectivas con las terapias dirigidas a los receptores de neuroquininas

  2026cites this paper
• Safety, Pharmacokinetics, and Pharmacodynamics of GS1-144, a Neurokinin-3 Receptor Antagonist: A Randomized Phase 1 Single and Multiple Ascending Dose and Food Effect Study.

  2026cites this paper
• Utilization of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms of menopause in a real-world setting.

  2026cites this paper
• The effect of a midwife-led education program on menopause symptom severity and menopause-specific quality of life: a randomized controlled longitudinal study.

  2026cites this paper
• [Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR, RNMOT, RAGG].

  2026cites this paper
• Virtual reality for menopause symptom management: opportunities, challenges, and next steps

  2025cites this paper
• Fezolinetant effect on vasomotor symptoms due to menopause in women unsuitable for hormone therapy

  2025cites this paper
• THE INFLUENCE OF OVARIAN ACTIVITY AND MENOPAUSE ON MENTAL HEALTH: EVIDENCE FROM ANIMAL MODELS AND WOMEN.

  2025cites this paper
• Fezolinetant’s efficacy and safety in treatment of vasomotor symptoms in postmenopausal women: a meta-analysis and GRADE evaluation of randomized controlled trials

  2025cites this paper
• An Open-Label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics and Safety of Fezolinetant in Healthy Chinese Female Subjects

  2025cites this paper
• Subjective menopausal hot flashes in sleep disturbance: does the timing of hot flashes matter?

  2025cites this paper
• Prevalence and impact of vasomotor symptoms associated with menopause among Nordic women: Subgroup analysis from an international cross‐sectional survey

  2025cites this paper
• Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: a comprehensive systematic review and meta-analysis of randomized controlled trials

  2025cites this paper
• Investigation of the quality of life and influencing factors among perimenopausal women

  2025cites this paper
• Prevalence and severity of menopausal symptoms in peri and post-menopausal women.

  2025cites this paper
• Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms

  2025cites this paper
• Treating moderate to severe menopausal vasomotor symptoms with fezolinetant: responder analysis of the phase 3b DAYLIGHT study

  2025cites this paper
• Thermal image edge detection for AI-powered medical research imaging

  2025cites this paper
• Metabolic and transcriptional effects of bazedoxifene/conjugated estrogens in a model of obesity-associated breast cancer risk

  2025cites this paper
• [Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP, RSMSI, RAGG].

  2025cites this paper
• Evolutionary Perspectives, Comparative Approaches, and the Lived Experience of Menopause.

  2025cites this paper
• Supporting women in relation to menopause knowledge and awareness: Lessons learned from a gender-specific educational programme

  2025cites this paper
• Benefits of Hormonal Contraception Across the Lifespan: A Case-Based, Interactive Curriculum

  2025cites this paper
• Targeting vasomotor symptoms with the new drug fezolinetant – an expert overview

  2025cites this paper
• Can menopausal hormone therapy be considered in postmenopausal women who are older than 60 years?

  2025cites this paper
• A Systematic Review of Anxiety and Depressive Symptoms Among Women Experiencing Vasomotor Symptoms Across Reproductive Stages in the US

  2025cites this paper
• Menopause and its effects on autonomic regulation of blood pressure: Insights and perspectives.

  2025cites this paper
• Characterization and Treatment Patterns of Peri/Menopausal and Postmenopausal Women with and Without Vasomotor Symptoms in a Retrospective Database Study

  2025cites this paper
• Pharmacotherapy of Perimenopausal and Menopausal Symptoms: An Overview

  2025cites this paper
• Not your mother's hormone therapy: Highly selective estrogen receptor beta agonists as next-generation therapies for menopausal symptom relief.

  2025cites this paper
• Distinguishing hot flashes and night sweats: a mixed-method analysis.

  2025cites this paper
• Menopause as a biological and psychological transition

  2025cites this paper
• An empowerment model for managing menopause.

  2024cites this paper
• Comparison of Healthcare Costs for Women with Treated Versus Untreated Vasomotor Symptoms Due to Menopause

  2024cites this paper
• Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper

  2024cites this paper
• Is Anxiety Associated with Vasomotor Symptoms in Postmenopausal Women with Insomnia Complaints?

  2024cites this paper
• Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies

  2024influential citation
• Prevalence and impact of vasomotor symptoms due to menopause among women in Canada: A subgroup analysis from an international cross-sectional survey of Women with Vasomotor Symptoms Associated with Menopause (WARM Study)

  2024cites this paper
• Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.

  2024cites this paper
• Menopausal women struggling with symptoms at work – a conundrum unsolved?

  2024cites this paper
• In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers

  2024cites this paper
• Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis

  2024cites this paper
• Prevalence and impact of vasomotor symptoms associated with menopause among women in Brazil: Subgroup analysis from an international cross-sectional survey.

  2024cites this paper
• Physical activity and menopausal symptoms: evaluating the contribution of obesity, fitness, and ambient air pollution status

  2024cites this paper
• Non-hormonal pharmacological interventions for managing vasomotor symptoms-how can we help: 2024 landscape.

  2024cites this paper
• Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms

  2024cites this paper
• The 100 top-cited articles in menopausal syndrome: a bibliometric analysis

  2024cites this paper
• Impact of Physical Exercise on Menopause Symptoms and Health-related quality of life - a literature review

  2024cites this paper
• Supplementation with cassis polyphenol has no effect on menopausal symptoms in healthy middle-aged women: A randomized, double-blind, parallel-group, placebo-controlled trial.

  2024cites this paper
• Epidemiology and clinical outcomes of vasomotor symptoms among perimenopausal women and women aged 65 years or older in the US: a systematic review

  2024cites this paper
• Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data

  2024cites this paper
• Uncovering gaps in management of vasomotor symptoms: findings from a national need assessment

  2024cites this paper
• Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials

  2024cites this paper
• Optimizing U-Net CNN performance: a comparative study of noise filtering techniques for enhanced thermal image analysis

  2024cites this paper
• Evolutionary Perspectives, Comparative Approaches, and the Lived Experience of Menopause.

  2024cites this paper
• Diretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024

  2024cites this paper
• Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2)

  2024cites this paper
• Brazilian Guideline on Menopausal Cardiovascular Health – 2024

  2024cites this paper
• Efficacy and safety of fezolinetant for moderate-severe vasomotor symptoms associated with menopause in individuals unsuitable for hormone therapy: phase 3b randomised controlled trial

  2024cites this paper
• Fear, misinformation, and pharmaceutical messianism in the promotion of compounded bioidentical hormone therapy

  2024cites this paper
• Endocrine effects of heat exposure and relevance to climate change

  2024cites this paper
• Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2)

  2024cites this paper
• A New Era in Menopause Management?

  2024cites this paper
• Genetic architecture of thoracic aortic dissection in the female population.

  2023cites this paper
• Assessment of women’s treatment preferences for vasomotor symptoms due to menopause

  2023cites this paper
• Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey

  2023cites this paper
• Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms

  2023cites this paper
• Российские критерии приемлемости назначения менопаузальной гормональной терапии пациенткам с сердечно-сосудистыми и метаболическими заболеваниями. Согласительный документ РКО, РОАГ, РАЭ, ЕАТ, РАФ

  2023cites this paper
• Nonhormonal medication treatment of VMS

  2023cites this paper
• Hormones and Aging: An Endocrine Society Scientific Statement.

  2023cites this paper
• Menopausal Vasomotor Symptoms and Plasma Alzheimer's Disease Biomarkers.

  2023cites this paper
• Menopausal Vasomotor Symptoms and Subclinical Atherosclerotic Cardiovascular Disease: A Population‐Based Study

  2023cites this paper
• Comparing long-term sexual dysfunction across different uterine cancer treatment modalities.

  2023cites this paper
• [Russian Eligibility Criteria for Prescribing Menopausal Hormone Therapy to Patients With Cardiovascular and Metabolic Diseases. Consensus Document of RSC, RSOG, RAE, EUAT, RAP].

  2023cites this paper
• Sleep During Menopause.

  2023cites this paper
• Prevalence and impact of vasomotor symptoms due to menopause among women in Brazil, Canada, Mexico, and Nordic Europe: a cross-sectional survey

  2023cites this paper
• Global view of vasomotor symptoms and sleep disturbance in menopause: a systematic review

  2023cites this paper
• Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.

  2023cites this paper
• Vasomotor symptoms and risk of cardiovascular disease in peri- and postmenopausal women: A systematic review and meta-analysis.

  2023cites this paper
• Hormone replacement therapy and cancer risks in perimenopausal women: A retrospective cohort study using a Japanese claims database

  2023cites this paper
• Vasomotor symptoms and their links to cardiovascular disease risk.

  2023cites this paper
• Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1)

  2023cites this paper
• Why is everyone talking about menopause?

  2023cites this paper
• Pomegranate effects on the health aspects of women during peri‐ and postmenopause: A systematic review and meta‐analysis

  2023cites this paper
• Effect of a lavender essential oil and sleep hygiene protocol on insomnia in postmenopausal women: A pilot randomized clinical trial.

  2023cites this paper
• Impact of Menopause Symptoms on Women in the Workplace.

  2023cites this paper
• Exploration of the association between menopausal symptoms, gastrointestinal symptoms, and perceived stress: survey-based analysis

  2023cites this paper
• Hot Flashes in Adolescence and Young Adult Females: a Link to Vitamin D and Calcium

  2022influential citation
• Psychometric properties of the French Hot Flash Related Daily Interference Scale (HFRDIS)

  2022cites this paper
• Persistent gap in menopause care 20 years after the WHI: a population-based study of menopause-related symptoms and their management.

  2022cites this paper
• Physical activity as a protective factor for climacteric symptoms

  2022cites this paper
• Low anti-Müllerian hormone levels are associated with an increased risk of incident early-onset vasomotor symptoms among premenopausal women

  2022cites this paper
• Diversity of menopause experience in the workplace: Understanding confounding factors

  2022cites this paper
• Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey.

  2022cites this paper
• Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States.

  2022cites this paper
• How Menopausal Symptoms are Related to Different Stages of Postmenopausal Years: A Study from Eastern India

  2022influential citation
• Estradiol and Progesterone (Bijuva)

  2022cites this paper
• Release Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual

  2022cites this paper